BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

562 related articles for article (PubMed ID: 20877357)

  • 1. How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine.
    Gerlinger M; Swanton C
    Br J Cancer; 2010 Oct; 103(8):1139-43. PubMed ID: 20877357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumour heterogeneity and the evolution of polyclonal drug resistance.
    Burrell RA; Swanton C
    Mol Oncol; 2014 Sep; 8(6):1095-111. PubMed ID: 25087573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolutionary scalpels for dissecting tumor ecosystems.
    Rosenbloom DIS; Camara PG; Chu T; Rabadan R
    Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):69-83. PubMed ID: 27923679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative Clinical Imaging Methods for Monitoring Intratumoral Evolution.
    Kim JY; Gatenby RA
    Methods Mol Biol; 2017; 1513():61-81. PubMed ID: 27807831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perturbation-Driven Entropy as a Source of Cancer Cell Heterogeneity.
    Nijman SMB
    Trends Cancer; 2020 Jun; 6(6):454-461. PubMed ID: 32460001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-tumour heterogeneity - going beyond genetics.
    Caiado F; Silva-Santos B; Norell H
    FEBS J; 2016 Jun; 283(12):2245-58. PubMed ID: 26945550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic heterogeneity and cancer drug resistance.
    Turner NC; Reis-Filho JS
    Lancet Oncol; 2012 Apr; 13(4):e178-85. PubMed ID: 22469128
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mathematical models of cell phenotype regulation and reprogramming: Make cancer cells sensitive again!
    Wooten DJ; Quaranta V
    Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):167-175. PubMed ID: 28396217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intratumor heterogeneity: evolution through space and time.
    Swanton C
    Cancer Res; 2012 Oct; 72(19):4875-82. PubMed ID: 23002210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population genetics perspective on the determinants of intra-tumor heterogeneity.
    Hu Z; Sun R; Curtis C
    Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):109-126. PubMed ID: 28274726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics.
    Lee AJ; Swanton C
    Biochem Pharmacol; 2012 Apr; 83(8):1013-20. PubMed ID: 22192819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of intra-clonal heterogeneity on the treatment of multiple myeloma.
    Brioli A; Melchor L; Cavo M; Morgan GJ
    Br J Haematol; 2014 May; 165(4):441-54. PubMed ID: 24580032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrating evolutionary dynamics into cancer therapy.
    Gatenby RA; Brown JS
    Nat Rev Clin Oncol; 2020 Nov; 17(11):675-686. PubMed ID: 32699310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Constraints in cancer evolution.
    Venkatesan S; Birkbak NJ; Swanton C
    Biochem Soc Trans; 2017 Feb; 45(1):1-13. PubMed ID: 28202655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catch my drift? Making sense of genomic intra-tumour heterogeneity.
    Sottoriva A; Barnes CP; Graham TA
    Biochim Biophys Acta Rev Cancer; 2017 Apr; 1867(2):95-100. PubMed ID: 28069394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment-Induced Mutagenesis and Selective Pressures Sculpt Cancer Evolution.
    Venkatesan S; Swanton C; Taylor BS; Costello JF
    Cold Spring Harb Perspect Med; 2017 Aug; 7(8):. PubMed ID: 28289245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of memory in non-genetic inheritance and its impact on cancer treatment resistance.
    Cassidy T; Nichol D; Robertson-Tessi M; Craig M; Anderson ARA
    PLoS Comput Biol; 2021 Aug; 17(8):e1009348. PubMed ID: 34460809
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC).
    Smith CIE
    Semin Cancer Biol; 2017 Aug; 45():36-49. PubMed ID: 27865897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Translational implications of tumor heterogeneity.
    Jamal-Hanjani M; Quezada SA; Larkin J; Swanton C
    Clin Cancer Res; 2015 Mar; 21(6):1258-66. PubMed ID: 25770293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overlooking evolution: a systematic analysis of cancer relapse and therapeutic resistance research.
    Aktipis CA; Kwan VS; Johnson KA; Neuberg SL; Maley CC
    PLoS One; 2011; 6(11):e26100. PubMed ID: 22125594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.